Jacob Bell
New Member
Author(s) Petrosino S, Ligresti A, Di Marzo V
Institution Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy. spetrosino@icmib.na.cnr.it
Source Curr Opin Chem Biol 2009 Jun; 13(3):309-20.
MeSH Amidohydrolases
Animals
Chemistry, Pharmaceutical
Drug Discovery
Endocannabinoids
Humans
Lipoprotein Lipase
Monoacylglycerol Lipases
Receptors, Cannabinoid
Abstract The identification of the major psychoactive constituent of Cannabis and marijuana, Delta(9)-tetrahydrocannabinol, opened the way first to the cloning of the G-protein-coupled cannabinoid CB(1) and CB(2) receptors, and then to the isolation and characterisation of their endogenous agonists, the endocannabinoids. Considerable progress has been made in the characterisation of pathways and enzymes for the biosynthesis and degradation of anandamide and 2-arachidonoylglycerol, the two best-known endocannabinoids, as well as of endocannabinoid-related molecules, such as the N-acylethanolamines, which, as in the case of N-palmitoylethanolamine and N-oleoylethanolamine, may interact with other receptor types. However, it is still not fully understood how other plant cannabinoids, of which cannabidiol is the most studied representative, exert their pharmacological effects. Together with these issues, this first review article on the endocannabinoids describes the synthetic pharmacological tools that have been designed so far to interact with the proteins of the 'endocannabinoid system' and that can potentially be used as templates for the development of new therapies.
Language eng
Pub Type(s) Journal Article
Review
PubMed ID 19457702
Source: Endocannabinoid chemical biology: a tool for the development of novel therapies
Institution Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Via Campi Flegrei 34, 80078 Pozzuoli, Naples, Italy. spetrosino@icmib.na.cnr.it
Source Curr Opin Chem Biol 2009 Jun; 13(3):309-20.
MeSH Amidohydrolases
Animals
Chemistry, Pharmaceutical
Drug Discovery
Endocannabinoids
Humans
Lipoprotein Lipase
Monoacylglycerol Lipases
Receptors, Cannabinoid
Abstract The identification of the major psychoactive constituent of Cannabis and marijuana, Delta(9)-tetrahydrocannabinol, opened the way first to the cloning of the G-protein-coupled cannabinoid CB(1) and CB(2) receptors, and then to the isolation and characterisation of their endogenous agonists, the endocannabinoids. Considerable progress has been made in the characterisation of pathways and enzymes for the biosynthesis and degradation of anandamide and 2-arachidonoylglycerol, the two best-known endocannabinoids, as well as of endocannabinoid-related molecules, such as the N-acylethanolamines, which, as in the case of N-palmitoylethanolamine and N-oleoylethanolamine, may interact with other receptor types. However, it is still not fully understood how other plant cannabinoids, of which cannabidiol is the most studied representative, exert their pharmacological effects. Together with these issues, this first review article on the endocannabinoids describes the synthetic pharmacological tools that have been designed so far to interact with the proteins of the 'endocannabinoid system' and that can potentially be used as templates for the development of new therapies.
Language eng
Pub Type(s) Journal Article
Review
PubMed ID 19457702
Source: Endocannabinoid chemical biology: a tool for the development of novel therapies
